Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which
prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell
activity, thus enhancing immune response and has potential to treat various types of tumors.